⛏🅾️Ⓜ️💣

#AVCT does not care about the short term price (2024/2025). @avacta is focused on (1) collecting as much data as possible, (2) protecting the IP & (3) selecting the right partner. Partner then swallows biotech. ‘100-baggers’ are not supposed to be easy. But I wish it was. 2/2

At this valuation + NASDAQ listed, specialist biotech investors jump in and push this up further. #AVCT management have done well to shift the company away from its previous “covid stock” labelling over the last 2 years. It’s now a focused clinical stage biotech with a “unique industry-leading technology platform”. Time to rerate this, @avacta.

At a £1B-£1.5B valuation, you raise say £100M, retain & advance 6103 through expansions whilst your partners (preclinical 6207(?) + 6000 phase 2) advance your two other assets. Auction kicks off and the numbers (£XXB) get silly.

Multiple deals are expected for #AVCT, including licensing the technology to a partner for use with their own payload, alongside a partner for AVA6000 Phase 2. The below was from a year ago. As I’ve said before, my view has been that Avacta needed to see the Gen 2 sustained release system “working” before signing off on any deals. With 7-8 weeks of clinical data now available on 6103/Gen 2, that window feels like it’s here, IMO. Exciting times to be an @avacta shareholder. Always DYOR.

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion. fiercebiotech.com/biotech/bms-in…

It’s worth noting that we don’t actually know whether they’ll sell these shares. Previously, traders often sold in anticipation because this happened every quarter. A lot of the recent volume may simply have been people positioning around that expectation. Given the improved relationship Avacta now appears to have with Heights, there’s a chance this situation could be quite different. For all we know they may ultimately become a key long term investor/ally.

@BigBiteNow Hopefully that’s the dumping of the 250k - 500k a day over the last couple of weeks.

This #AVCT share conversion (which I assume has been sold down) potentially acts as a temporary drag on the share price, but as things stand, that is all it is. It also gradually removes the debt burden, which is no bad thing. The conversion price was always known, so it is not new news. I remain convinced that the pending data drop on AVA6000, plus the growing time served by AVA6103, will be the biggest driver, so temporary is the keyword here. londonstockexchange.com/news-article/A…

This was last year’s prelim presentation. Lots in there. avacta.com/wp-content/upl…

Science Day video presentation ☑️ Prelim presentation + Q&A ☑️ ASCO 6000 data ☑️ An action packed couple of weeks for #AVCT

@drewster_1965 @JStonker Yes. He even presented at their poster session in October.

@JStonker Has Dr Tap not kept going with AVA6000? That wouldn't sit well.

New STS study co-authored by W Tap, added to NLM today. Palbociclib + retifanlimab met primary endpoint in Phase 2 but 77% stopped due to progression and ~20% stopped due to toxicity. Bar remains low for STS. #AVCT pmc.ncbi.nlm.nih.gov/articles/PMC13…

"Importantly, the fact that two sets of new data are being presented, suggests that either STS or TNBC - or both! - have also performed very well in the Phase 1b." A great point. I wonder if we'll have a "fuller" data package i.e including some ovarian patients too. Primary: SGC Secondary: TNBC, STS, Ovarian CC mentioned Ovarian in the recent interview with @chrisleidli when speaking about 6000 indications. I had not heard this mentioned in a while. Plus, it's included on here (image below): withpower.com/trial/phase-1-…

x2 new data dumps (at separate oncology conferences, TBA) before end June for AVA6000, according to #AVCT's CEO at Science Day. Presumably, SCG as a standalone indication (given it is the lead for 6K at the moment) at the first conference, and then STS and TNBC packaged together for the second conference? Importantly, the fact that two sets of new data are being presented, suggests that either STS or TNBC - or both! - have also performed very well in the Phase 1b. Besides that, I'm hoping we see Fast Track, possibly Breakthrough Therapy, Designation for 6K SGC, announced shortly. [There's a recent clip of CC on this platform somewhere hinting at that.] So much to look forward to. ...... Here's my semi-regular reminder that there are, as of mkt close yesterday, currently... *checks the list*... 130 biotechs listed on NASDAQ that have revenue of sub $100m, and that have a mkt cap greater than Avacta. Oncology is the largest therapeutic area in global pharma by annual revenue. It also dominates R&D pipelines (accounting for circa 40% of drugs in development). Ergo, one would think that the company with the most targeted, most versatile, and most broadly applicable delivery platform for that leading therapeutic area, would be near the very top of that list of highest mkt caps. The potential upside here in a relatively short timeframe (<2 years) is just absurd. How long can Avacta hold onto the pre|CISION platform whilst remaining independent, is the key question now.

The market knows AVA6000 data is scheduled to be released in the next 6 weeks, plus AVA6103 continues adding time served, so I don't think #AVCT is finished here.

@BigBiteNow I'm looking forward to the video(s) from Science Day this week or next. There should be plenty of nuggets in there to support a near term move above 100p, especially alongside AVA6000 data in a couple of weeks, which could trigger additional news flow...

@JStonker They should sell Affimer tech off ($XXXM) and plough it into preCISION.

Affyxell signing joint research and development and licensing agreement with ProAppTech for next-generation protein degradation drugs - announced today in Korea. newsis.com/view/NISX20260… #AVCT

@PJ_Crabb Hi Paul, not bad, cheers. Hope you’re well too. 20 trial sites planned for 6103 next year.

@tom_the_bomb__ Hi Tom, hope you’re well. What does the 20 refer to and huge planned scale up?

#AVCT ⏰ 👀

@Blueberrymgmnt I saw this the other day too: investments.halifax.co.uk/research-centr… "Merck & Co to spin off cancer unit ahead of Keytruda patent cliff."

Interesting oncology collab: Erasca + Merck pairing ERAS0015 with KEYTRUDA in RAS mutant tumors. Suggests there’s more than one way to commercialise promising science. Strategic partnerships may be just as important as going it alone. #AVCT

Independent peer reviewed (University of Copenhagen) review published last week confirming FAP is expressed across ~90% of epithelial cancers at 10-100x normal tissue levels. sciencedirect.com/science/articl… FAP as a target independently validated. #AVCT

@SeanDentBsc Perhaps the market is finally realising that the tech will totally disrupt the ADC market.

The last time #AVCT was in the 100s was early 2024. Since then, the progress made by @avacta has been significant. The next 6 months are loaded up with catalysts. The valuation disconnect can't continue to be ignored. C'mon the Avacta ⏰🚀

@massivefanNWO @clear_cap It clearly lacks any fundamental insight. Purely technical/chart based. I don’t think any investor would sell at 108p. Only those trading it.

@tom_the_bomb__ @clear_cap 108p target 😝 They clearly have no idea as to what they are covering. Understand the real investment hypothesis and you sell the house and buy Avacta! I won’t be taking their advice and sell at 108! 😂

Analysts will probably never publish the kinds of numbers large pharma will be running internally right now for #AVCT, but it’s still good to see @clear_cap targeting a +30% move from here in their “small caps to buy” for May. #EveryLittleHelps #Biotech #StocksToBuy